Dierks C, Seufert J, Aumann K, Ruf J, et al. The Lenvatinib/Pembrolizumab combination is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 2021 Jan 28. doi: 10.1089/thy.2020.0322.
PMID: 33509020